Lexeo Financial Statements From 2010 to 2025

LXEO Stock   2.96  0.15  4.82%   
Lexeo Therapeutics, financial statements provide useful quarterly and yearly information to potential Lexeo Therapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexeo Therapeutics, financial statements helps investors assess Lexeo Therapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexeo Therapeutics,'s valuation are summarized below:
Market Capitalization
254.2 M
Enterprise Value Revenue
416.3418
Earnings Share
(12.53)
We have found one hundred twenty available fundamental ratios for Lexeo Therapeutics,, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lexeo Therapeutics,'s last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Enterprise Value is likely to drop to about 153.1 M

Lexeo Therapeutics, Total Revenue

0.0

Check Lexeo Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics,'s main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 3.2 M or Depreciation And Amortization of 2.2 M, as well as many indicators such as Price To Sales Ratio of 369, Dividend Yield of 0.0 or PTB Ratio of 2.98. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Lexeo Therapeutics, Correlation against competitors.

Lexeo Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets110.9 M160.8 M60.6 M
Slightly volatile
Short and Long Term Debt Total10.3 M13.4 MM
Slightly volatile
Other Current Liabilities6.4 M12.3 M2.9 M
Slightly volatile
Total Current Liabilities10.9 M19.8 M4.8 M
Slightly volatile
Current Deferred Revenue12.9 M12.3 M2.9 M
Slightly volatile
Accounts Payable2.6 M4.4 M1.1 M
Slightly volatile
Cash100.1 M139.7 M56.1 M
Slightly volatile
Non Current Assets TotalM17.8 M3.7 M
Slightly volatile
Non Currrent Assets Other3.9 M3.7 M887.6 K
Slightly volatile
Cash And Short Term Investments100.1 M139.7 M56.1 M
Slightly volatile
Common Stock Shares Outstanding27.7 M30.6 M25.4 M
Slightly volatile
Liabilities And Stockholders Equity110.9 M160.8 M60.6 M
Slightly volatile
Non Current Liabilities Total7.7 M8.1 M48.9 M
Pretty Stable
Other Current Assets1.8 M3.3 M734.1 K
Slightly volatile
Other Stockholder Equity187.8 M178.9 M32.8 M
Slightly volatile
Total Liabilities22.5 M23.6 M53.7 M
Pretty Stable
Total Current Assets101.9 M142.9 M56.8 M
Slightly volatile
Capital Stock2.4 K3.5 K1.9 K
Slightly volatile
Net Working Capital90.9 M123.1 M52 M
Slightly volatile
Short Term Debt2.8 MM1.3 M
Slightly volatile
Common Stock2.4 K3.5 K1.9 K
Slightly volatile

Lexeo Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.2 M2.1 M462.1 K
Slightly volatile
Selling General Administrative9.7 M17.7 M4.4 M
Slightly volatile
Other Operating Expenses51.4 M78.8 M23 M
Slightly volatile
Research Development41.7 M61.1 M18.6 M
Slightly volatile
Total Operating Expenses50.9 M76.7 M22.7 M
Slightly volatile
Interest Income3.5 M3.3 M695.7 K
Slightly volatile
Cost Of Revenue1.1 M2.1 M398.1 K
Slightly volatile

Lexeo Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Working Capital1.9 M1.3 M887 K
Slightly volatile
Begin Period Cash Flow67.6 M92.7 M25.5 M
Slightly volatile
Issuance Of Capital Stock77.4 M115.3 M48.4 M
Slightly volatile
Total Cash From Financing Activities79 M119.4 M50.6 M
Slightly volatile
End Period Cash Flow101.9 M143.4 M56.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio369436436
Slightly volatile
Average Payables1.2 M1.4 M1.5 M
Slightly volatile
Stock Based Compensation To Revenue2.572.450.8289
Slightly volatile
Capex To Depreciation0.09780.110.9133
Slightly volatile
EV To Sales285324371
Slightly volatile
Payables Turnover0.250.440.1035
Slightly volatile
Sales General And Administrative To Revenue17.3416.525.7248
Slightly volatile
Research And Ddevelopement To Revenue71.0467.6525.4931
Slightly volatile
Capex To Revenue1.31.240.4161
Slightly volatile
Cash Per Share2.884.12.0799
Slightly volatile
Days Payables Outstanding82186462.7 K
Slightly volatile
Income Quality0.660.810.678
Slightly volatile
Net Debt To EBITDA3.081.894.6044
Slightly volatile
Current Ratio7.888.2931.9327
Slightly volatile
Capex Per Share0.00680.00710.0093
Pretty Stable
Revenue Per Share0.03060.02390.0254
Slightly volatile
Interest Debt Per Share0.30.40.2283
Slightly volatile
Debt To Assets0.120.09570.1064
Pretty Stable
Days Of Payables Outstanding82186462.7 K
Slightly volatile
Ebt Per Ebit1.121.111.0958
Slightly volatile
Quick Ratio7.888.2931.9327
Slightly volatile
Cash Ratio7.78.131.8475
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0206
Slightly volatile
Fixed Asset Turnover0.05190.05467.1548
Slightly volatile
Debt Ratio0.120.09570.1064
Pretty Stable
Price Sales Ratio369436436
Slightly volatile
Asset Turnover0.01340.00770.015
Slightly volatile

Lexeo Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap220.3 M321.8 M257.7 M
Slightly volatile
Enterprise Value153.1 M223 M209.8 M
Slightly volatile

Lexeo Fundamental Market Drivers

Cash And Short Term Investments121.5 M

Lexeo Upcoming Events

4th of November 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of November 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lexeo Therapeutics, Financial Statements

Lexeo Therapeutics, investors utilize fundamental indicators, such as revenue or net income, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12.3 M12.9 M
Cost Of Revenue2.1 M1.1 M
Stock Based Compensation To Revenue 2.45  2.57 
Sales General And Administrative To Revenue 16.52  17.34 
Research And Ddevelopement To Revenue 67.65  71.04 
Capex To Revenue 1.24  1.30 
Revenue Per Share 0.02  0.03 
Ebit Per Revenue(106.40)(101.08)

Pair Trading with Lexeo Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lexeo Stock

  0.89ME 23Andme HoldingPairCorr

Moving against Lexeo Stock

  0.83VALN Valneva SE ADRPairCorr
  0.71DVAX Dynavax TechnologiesPairCorr
  0.57DMAC DiaMedica TherapeuticsPairCorr
  0.54VIGL Vigil NeurosciencePairCorr
  0.39EQ EquilliumPairCorr
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lexeo Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics, Common Stock:
Check out the analysis of Lexeo Therapeutics, Correlation against competitors.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.53)
Return On Assets
(0.40)
Return On Equity
(0.75)
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.